ArticleMolecular biology reports2025
Mechanism of ABCD3 inhibiting colorectal cancer progression by regulating Wnt/β-catenin.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAccumulating evidence highlights the critical role of dysregulated Wnt/β-catenin signaling in colorectal cancer (CRC) pathogenesis. However, the clinical translation of therapeutics targeting this pathway remains challenging. While ABCD3 is known to modulate the Wnt/β-catenin signaling pathway and influence CRC progression, its precise molecular regulatory mechanisms and prognostic significance require further elucidation. This study further elucidates the mechanism by which the ABCD3 gene mediates CRC progression through regulation of the Wnt/β-catenin pathway. METHODS AND
resultsIntegrated analysis of TCGA transcriptomic data using weighted gene co-expression network analysis (WGCNA) identified ABCD3 as a hub gene within the CRC prognostic model. ABCD3 downregulation in CRC was systematically validated through three complementary approaches: Western blot for protein quantification, RT-PCR for transcriptional profiling, and immunohistochemical evidence from the Human Protein Atlas database. To investigate its functional role, ABCD3 knockdown was performed using siRNA in HT29 and HCT15 cell lines. Subsequent functional characterization revealed that ABCD3 suppression significantly attenuated cellular proliferation (CCK-8 assay) and concomitantly reduced invasive and migratory capacities in Transwell assays.
conclusionsBased on the CRC prognostic model, ABCD3 was identified as a significant prognostic factor, with low expression associated with poorer prognosis. Functional analysis demonstrated an anti-tumor role for ABCD3 in CRC pathogenesis, mediated through suppression of Wnt/β-catenin signaling, which effectively mitigates malignant CRC behavior. These findings suggest that targeting this ABCD3-Wnt/β-catenin regulatory axis represents a novel strategy for precision treatment of CRC.
Indexed as
Identifiers
40668324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.